Cagrilintide: an amylin analogue in metabolic research

Most of the attention in metabolic peptide research has gone to the incretin hormones. Cagrilintide comes from a different hormone family entirely: amylin. That distinct origin is why researchers study it alongside, rather than instead of, the leading metabolic peptides.

What amylin is

Amylin is a hormone co-secreted with insulin by the pancreas in response to food. In laboratory models it is studied for its role in satiety signalling and in slowing gastric emptying — effects that complement, rather than duplicate, those of the incretin hormones. Cagrilintide is a synthetic long-acting analogue of this hormone.

Why an analogue is used

Native amylin is unstable and prone to aggregation, which makes it impractical in controlled experiments. Cagrilintide was engineered as a more soluble, longer-lasting analogue, giving researchers a stable tool to probe amylin-receptor biology in study models.

A complementary research pathway

Because amylin acts through a different receptor system, cagrilintide is frequently studied in combination with metabolic peptides such as semaglutide. In the published research literature, engaging both pathways together has drawn interest for its combined effect on metabolic markers in study models. Our articles on metabolic research peptides and receptor pathways set out the neighbouring pathways.

Form and reconstitution

Cagrilintide is supplied as a lyophilised (freeze-dried) powder for stability and reconstituted with bacteriostatic water before use. Our reconstitution and storage guide covers the method, and every Vela order includes a free 3 mL vial of bacteriostatic water.

Documented quality

Every Vela batch of cagrilintide ships with a certificate of analysis issued within six months of sale, documenting identity and purity for reproducible work.